| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | -30.93% | UBS | $29 → $30 | Maintains | Sell |
| 07/27/2023 | 28.93% | JP Morgan | $45 → $56 | Maintains | Neutral |
| 07/12/2023 | -10.21% | Morgan Stanley | $29 → $39 | Maintains | Underweight |
| 07/12/2023 | -7.91% | Goldman Sachs | $35 → $40 | Maintains | Sell |
| 06/27/2023 | -33.23% | Morgan Stanley | $29 → $29 | Reiterates | Underweight → Underweight |
| 04/27/2023 | -14.82% | Keefe, Bruyette & Woods | $40 → $37 | Maintains | Underperform |
| 04/12/2023 | -33.23% | Morgan Stanley | $30 → $29 | Maintains | Underweight |
| 03/24/2023 | -17.12% | Goldman Sachs | $40 → $36 | Maintains | Sell |
| 02/09/2023 | -3.3% | Goldman Sachs | $38 → $42 | Maintains | Sell |
| 01/11/2023 | -14.82% | Goldman Sachs | $40 → $37 | Downgrades | Neutral → Sell |
| 01/09/2023 | -30.93% | UBS | $32 → $30 | Maintains | Sell |
| 11/03/2022 | -7.91% | JP Morgan | $42 → $40 | Maintains | Neutral |
| 11/03/2022 | -14.82% | Keefe, Bruyette & Woods | $40 → $37 | Downgrades | Market Perform → Underperform |
| 10/07/2022 | -12.51% | Goldman Sachs | $43 → $38 | Maintains | Neutral |
| 09/23/2022 | -19.42% | UBS | $43 → $35 | Downgrades | Neutral → Sell |
| 07/28/2022 | -1% | UBS | $40 → $43 | Maintains | Neutral |
| 07/18/2022 | -17.12% | Morgan Stanley | $53 → $36 | Downgrades | Equal-Weight → Underweight |
| 07/11/2022 | -3.3% | Wolfe Research | → $42 | Downgrades | Peer Perform → Underperform |
| 07/08/2022 | 3.6% | Piper Sandler | $50 → $45 | Maintains | Neutral |
| 07/06/2022 | -7.91% | UBS | $54 → $40 | Downgrades | Buy → Neutral |
| 04/28/2022 | 15.11% | Piper Sandler | → $50 | Downgrades | Overweight → Neutral |
| 04/12/2022 | 3.6% | Goldman Sachs | $50 → $45 | Maintains | Neutral |
| 04/07/2022 | 19.72% | Piper Sandler | $61 → $52 | Maintains | Overweight |
| 04/06/2022 | 31.23% | Keefe, Bruyette & Woods | → $57 | Downgrades | Outperform → Market Perform |
| 03/09/2022 | 40.44% | Piper Sandler | $70 → $61 | Maintains | Overweight |
| 03/08/2022 | 22.02% | Morgan Stanley | $65 → $53 | Maintains | Equal-Weight |
| 02/11/2022 | 61.16% | Piper Sandler | $78 → $70 | Upgrades | Neutral → Overweight |
| 02/10/2022 | 49.65% | Morgan Stanley | $68 → $65 | Maintains | Equal-Weight |
| 01/06/2022 | 49.65% | Goldman Sachs | $68 → $65 | Upgrades | Sell → Neutral |
| 01/04/2022 | 68.07% | UBS | $85 → $73 | Maintains | Buy |
| 12/17/2021 | 77.28% | Keefe, Bruyette & Woods | → $77 | Upgrades | Market Perform → Outperform |
| 12/08/2021 | 56.56% | Morgan Stanley | $75 → $68 | Maintains | Equal-Weight |
| 10/11/2021 | 56.56% | Morgan Stanley | $63 → $68 | Maintains | Equal-Weight |
| 07/22/2021 | 45.04% | Morgan Stanley | $60 → $63 | Maintains | Equal-Weight |
| 06/17/2021 | 45.04% | Wolfe Research | → $63 | Upgrades | Underperform → Peer Perform |
| 04/09/2021 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 04/07/2021 | 38.14% | Morgan Stanley | $57 → $60 | Maintains | Equal-Weight |
| 02/11/2021 | 31.23% | Morgan Stanley | $55 → $57 | Maintains | Equal-Weight |
| 01/11/2021 | 26.63% | Morgan Stanley | $52 → $55 | Maintains | Equal-Weight |
| 01/07/2021 | 15.11% | JP Morgan | $34 → $50 | Upgrades | Underweight → Neutral |
| 01/05/2021 | 28.93% | UBS | $40 → $56 | Upgrades | Neutral → Buy |
| 12/16/2020 | — | Seaport Global | Initiates Coverage On | → Neutral | |
| 12/14/2020 | 19.72% | Morgan Stanley | $41 → $52 | Maintains | Equal-Weight |
| 10/27/2020 | -5.61% | Piper Sandler | $37 → $41 | Maintains | Neutral |
| 10/12/2020 | -5.61% | Morgan Stanley | $29 → $41 | Maintains | Equal-Weight |
| 10/09/2020 | -3.3% | JMP Securities | $37 → $42 | Maintains | Market Outperform |
| 10/09/2020 | — | Keefe, Bruyette & Woods | Downgrades | Outperform → Market Perform | |
| 08/05/2020 | -44.75% | Goldman Sachs | $27 → $24 | Downgrades | Neutral → Sell |
| 07/30/2020 | -28.63% | Piper Sandler | $32 → $31 | Maintains | Neutral |
| 07/30/2020 | -33.23% | Morgan Stanley | $31 → $29 | Maintains | Equal-Weight |
| 07/13/2020 | -37.84% | Goldman Sachs | $34 → $27 | Downgrades | Buy → Neutral |
| 07/10/2020 | -26.33% | Piper Sandler | $40 → $32 | Downgrades | Overweight → Neutral |
| 07/07/2020 | -40.14% | JP Morgan | $20 → $26 | Downgrades | Neutral → Underweight |
| 04/09/2020 | -28.63% | Morgan Stanley | $37 → $31 | Maintains | Equal-Weight |
| 04/09/2020 | -10.21% | JMP Securities | $45 → $39 | Maintains | Market Outperform |
| 03/25/2020 | -35.54% | UBS | $33 → $28 | Maintains | Neutral |
| 02/06/2020 | 12.81% | JP Morgan | $44 → $49 | Maintains | Overweight |
| 02/06/2020 | -5.61% | Buckingham Research | $39 → $41 | Maintains | Buy |
| 12/11/2019 | -19.42% | Morgan Stanley | $37 → $35 | Maintains | Equal-Weight |
| 11/20/2019 | -14.82% | Morgan Stanley | $39 → $37 | Maintains | Equal-Weight |
| 10/09/2019 | -10.21% | Buckingham Research | $44 → $39 | Maintains | Buy |
| 10/08/2019 | -10.21% | Morgan Stanley | $41 → $39 | Maintains | Equal-Weight |
| 07/31/2019 | -10.21% | Keefe, Bruyette & Woods | $42 → $39 | Downgrades | Outperform → Market Perform |
| 07/11/2019 | 1.3% | Buckingham Research | $53 → $44 | Maintains | Buy |
| 07/08/2019 | -5.61% | Morgan Stanley | $45 → $41 | Maintains | Equal-Weight |
| 04/11/2019 | — | B of A Securities | Downgrades | Buy → Underperform | |
| 04/08/2019 | 15.11% | JMP Securities | $56 → $50 | Maintains | Market Outperform |
| 01/08/2019 | 5.91% | Morgan Stanley | $59 → $46 | Maintains | Equal-Weight |
| 11/06/2018 | 22.02% | Goldman Sachs | → $53 | Initiates Coverage On | → Buy |
| 10/23/2018 | 24.32% | UBS | $59 → $54 | Maintains | Neutral |
| 10/08/2018 | 35.84% | UBS | $62 → $59 | Maintains | Neutral |
What is the target price for Moelis (MC)?
The latest price target for Moelis (NYSE: MC) was reported by UBS on October 3, 2023. The analyst firm set a price target for $30.00 expecting MC to fall to within 12 months (a possible -30.93% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Moelis (MC)?
The latest analyst rating for Moelis (NYSE: MC) was provided by UBS, and Moelis maintained their sell rating.
When is the next analyst rating going to be posted or updated for Moelis (MC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moelis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moelis was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
Is the Analyst Rating Moelis (MC) correct?
While ratings are subjective and will change, the latest Moelis (MC) rating was a maintained with a price target of $29.00 to $30.00. The current price Moelis (MC) is trading at is $43.44, which is out of the analyst's predicted range.